Kornimate/medical-research-clean huggingface dataset:
central motor mechanisms in ais via hd-semg, eeg and neuromuscular coupling analysis

Conditions: Adolescent Idiopathic Scoliosis

Summary: 1. verifying the motor control effects of spinal manipulation on ais using outpatient and inpatient ais patients from our department as the study subjects, standardized spinal manipulation treatment is applied. the efficacy is evaluated through a combination of clinical outcome measures, hd-emg for paraspinal muscle function assessment, and pro-kin balance system for trunk stability analysis. this establishes an ais efficacy platform to further clarify the effectiveness of spinal manipulation in motor control regulation of ais. 2. investigating the central motor network's response to spinal manipulation in ais utilizing high-density semg-eeg technology, synchronized brain and muscle electrical signals are collected before and after treatment. by employing a neuromuscular synchronization and coupling analysis approach that integrates linear and nonlinear methods, the characteristic indices of information interaction between the central system and muscles are identified. this further explores the motor control and response characteristics of the muscle-cortex network to spinal manipulation in ais.


Eligibility criteria:
inclusion criteria: 1. patients aged ≥10 years; 2. risser sign grade 0-3; 3. cobb angle between 10° and 40°; 4. no prior treatment; 5. female patients within 1 year after menarche or before menstruation; 6. the patient's guardian signs the informed consent form for treatment. exclusion criteria: 1. those who do not meet the diagnostic criteria for ais or inclusion criteria; 2. patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, and hematopoietic system disorders, or those with mental illnesses; 3. patients with thrombocytopenia, coagulation disorders, or a tendency to bleed; 4. patients who are afraid of the treatment and cannot tolerate it; 5. those who have already received other treatments that may affect the study's outcome measures.
clinical pathway with "fast-track" in uncomplicated acute appendicitis

Conditions: Uncomplicated Acute Appendicitis

Summary: the aim of this study is to reduce the postoperative hospital stay, without increasing morbidity and mortality postoperative, expressed in terms of rate of complications and readmissions.


Eligibility criteria:
inclusion criteria: * patients diagnosed with uncomplicated acute appendicitis urgently. * signing the consent of participation and commitment to attend reviews. exclusion criteria: * suspected liver disease. * coagulation disorders. * patients in septic shock. * pregnant patients. * patients with symptoms compatible with acute uncomplicated appendicitis (plastron appendix, perforated appendicitis or diffuse peritonitis), or had 5 to more days of evolution). * no sign consent for participation in it.

Keywords: acute appendicitis appendectomy fast-track clinical pathway
phase iii, study to evaluate the efficacy of two different hbv vaccination schemes in patients with hepatic cirrhosis

Conditions: Hepatitis B; Cirrhosis; Awaiting Organ Transplant

Summary: the objective of this clinical trial is to compare the response rate obtained with two different vaccination schemes against hbv in cirrhotic patients. these patients must be candidates for liver transplantation, who have failed seroconversion (anti-hbs \< 10 iu/ml) after three intramuscular doses of 40 µg.


Eligibility criteria:
inclusion criteria: 1. cirrhotic patients, potential candidates for liver transplantation, with indication to hbv vaccination (hbsag negative and anti-hbs negative). 2. patients under treatment with hbvaxpro® who do not show a response after the first cycle of vaccination of three intramuscular doses of 40 µg at 0, 1 and 2 months. 3. patients over 18 years old. 4. negative pregnancy test. 5. patients who have given their consent to participate in the study. exclusion criteria: 1. absolute contraindication to hbv vaccine. 2. medical history of allergy to any component of the vaccine. 3. chronic renal failure on hemodialysis. 4. presence of antibodies against human immunodeficiency virus. 5. patients with seroconversion (anti-hbs \> 10 iu /ml) after the first three doses of vaccine. 6. lack of consent to participate in the study.
changes in cognition in hcv patients after virus eradication with direct antiviral agents

Conditions: HCV Infection; HCV Coinfection

Summary: study about the improvement of cognitive, psychopathological and functional abilities in hepatitis c virus (hcv) infected patients after eradication of the virus with direct antiviral agents.

the aim of this study is to investigate the effect that the eradication of the hcv has on cognition, quality of life and psychopathology. at the same time, investigators intend to study the association between cognitive changes and some clinical variables. the sample consists of 80 subjects (40 hcv patients and 40 hcv patients coinfected with the human immunodeficiency virus, hiv). exclusion criteria: cirrhosis, presence of minimal hepatic encephalopathy or active drug consumption. a neuropsychological assessment is made before the treatment with direct antiviral agents to evaluate memory, executive functions, processing speed, anxiety, depression and quality of life. additionally, the following clinical variables are collected: viral charge, immunosuppression (measured with t cells cd4 (cd4), cd4 nadir and t cells cd8 (cd8)) and fibrosis level, hcv genotype and plasma biomarkers: brain-derived neurotrophic factor (bdnf), interleukine 6 (il6), tumor necrosis factor (tnf-a),glial fibrillary acidic protein (gfap), soluble cd14 (scd14), neuro-specific enolase (nse). the second neuropsychological assessment and clinical data collection is carried out after treatment, concretely 6 months after hcv is undetectable in plasma.

Eligibility criteria:
inclusion criteria: * patients over 18 years old with indication to receive antiviral treatment * diagnosis of chronic infection by hepatitis c virus in the fibrous phase f3 or f4 that have not presented any clinical decompensation of their liver disease, with or without hiv co-infection exclusion criteria: * active alcohol consumption\> 40g daily or history of chronic alcoholism * active consumption of other toxics (heroin, cocaine, cannabis) * patients with minimum hepatic encephalopathy * background of cerebral neurological disease, chronic renal insufficiency and / or psychiatric illnesses assessed according to the diagnostic and statistical manual of mental disorders (dsm-5) criteria, which can affect cognitive functions. * active use of psychotropics or benzodiazepines
health app data collection study

Conditions: Cardiac Disease

Summary: utilization of additional wearable data to improve clinical outcome

in addition to information available from cardiac implantable medical devices, health related data available from commercially approved wearables and devices such as apple watch, blood pressure monitor and scales could be used to improve predictive analytics of impending clinical events. this study is to merge implantable medical device data with wearable data to evaluate the added benefit of extra data.

Eligibility criteria:
inclusion criteria: * patients are willing to be compliant with daily measurements required 18 years of age or older * patients who have been implanted with abt crt-d devices connected to merlin.net * patients who had at least one hf clinical event during past 12 calendar months * must provide written informed consent prior to the commencement of this clinical feasibility study * patients are willing to be compliant with daily measurements required exclusion criteria: * pregnant and/or lactating mothers will be excluded from the study or have a plan to be pregnant in the next 12 months * patients with a life expectancy less than the duration of the study, as per clinician's discretion. * patients who will not be able to complete the daily survey questions due to inability to read
study of clinical non-inferiority of actparin® (laboratorio bergamo) compared to heparin sodium (app pharmaceuticals), in patients with chronic renal failure

Conditions: Chronic Renal Failure

Summary: the purpose of this study is to investigate clinical non-inferiority, pharmacodynamic effect and safety of actparin® (heparin sodium - laboratório químico farmacêutico bergamo ltd.) compared to heparin sodium (app pharmaceuticals) in patients with renal failure under hemodialysis treatment.


Eligibility criteria:
inclusion criteria: * patients research that agree to participate in the study and sign the informed consent form; * patients aged over 18 years, both sexes, regardless of color or social class; * patients with impaired renal function in chronic hemodialysis schedule of at least 3 times a week and giving the use of heparin in the prophylaxis of thrombosis in the system; * patients with laboratory results within specified acceptance criteria. exclusion criteria: * patients who are taking part or took part in another clinical investigational study within 12 months; * hypersensitivity to heparin sodium and/or benzyl alcohol; * history of active hemorrhage with alteration of blood coagulation, such as genetic disorders of coagulation system; * history of disease that could aggravate or terminate the clinical manifestations, such as active peptic or gastric ulcer; * severe liver disease; * patients in cancer treatment; * pregnant and lactating women; * use of glucocorticoids over physiological dose; * use of other anticoagulants; * patients undergoing any surgery performed less than 15 days; * history of non response or exacerbated response to heparin sodium; * patients who do not adapt to 150 ui/kg dose.

Keywords: heparin renal insufficiency, chronic extracorporeal dialysis fibrinolytic agents anticoagulants aptt
a phase ⅱ study of f520 in patients with urothelial carcinoma

Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma

Summary: this is a multicenter, phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(pd-1) monoclonal antibody f520 in participants with locally advanced or metastatic urothelial cancer (uc).


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed,locally advanced（t4b,any n or any t,n2-3 or metastatic carcinoma（including renal pelvic, ureter bladder and urethra）; 2. cohort 1：patients with first-line platinum ineligible must meet criteria for either option a or option b (below): 1. has a tumor(s) with pd-l1 combined positive and is considered ineligible to receive cisplatin-based combination therapy, based on 1 of the following: * eastern cooperative oncology group (ecog) performance status (ps) score of 2 within 7 days prior to randomization * national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 grade ≥2 audiometric hearing loss * nci ctcae version 5.0 grade ≥2 peripheral neuropathy or 2. in the opinion of the investigator, is considered ineligible to receive any platinum-based chemotherapy (i.e., ineligible for cisplatin and carboplatin) based on: * ecog ps of 2 within 7 days prior to randomization. and ≥1 of the following: * documented visceral metastatic disease * nci ctcae version 5.0 grade ≥2 audiometric hearing loss * nci ctcae version 5.0 grade ≥2 peripheral neuropathy cohort 2: inoperable patients in sencond line（or beyond）with locally advanced or metastatic urothelial carcinoma who have disease recurrence or progression during or after a platinum-based chemotherapy regimen; * eastern cooperative oncology group (ecog) performance status (ps) score of 0 or 1 * calculated creatinine clearance ≥ 30 milliliter (ml)/min (cockcroft-gault formula) exclusion criteria: 1. has received prior therapy with an anti-pd-1, anti-pd-l1 agent or with ctla-4 receptor; 2. has a known hypersensitivity to anti-pd-1 / pd-l1 agent; 3. known pia meningeal metastasis or active central nervous system (cns) metastasis revealed by ct or mri. participants with asymptomatic brain metastases may participate without evidence of progression for at least 1 month. note: other protocol defined inclusion/exclusion criteria may apply.
mhealth biometrics for young people with obesity (motivate- loop)

Conditions: Obesity, Adolescent

Summary: the investigators aim to undertake a feasibility randomised controlled trial (rct) to investigate whether mhealth technology, allowing biometric informed feedback and coaching on exercise and pa, can be incorporated into the existing liverpool overweight and obesity programme (loop) at alder hey children's hospital. the overall objective is to have an evidence-based exercise and pa intervention ready to evaluate in a future rct.

the study will recruit patients from the liverpool overweight and obesity programme at alder hey children's hospital (loop@ alder hey). 40 participants will be recruited and randomly assigned to one of two groups (control n=20, intervention n=20). patients in the control group will continue to follow the loop@ alder hey programme but physical activity sessions will be monitored during the 12-week intervention using a heart rate monitor. importantly, the heart rate monitor will not provide any feedback to the patient. the intervention group will be provided with exercise counselling and to support this they will also be provide with a wristwatch that can monitor everyday activity and their heart rate, a smartphone app and access to a website. the intervention group will also participate in 5 consultations with an exercise specialist to plan their exercise programme and be updated on their progress towards physical activity targets. weekly text message updates will also provide feedback to the intervention group with participants able to respond to these updates. before and after the 3-month supported interventions, volunteers will participate in testing to assess changes in physical activity, blood pressure, glycaemia control, body composition and health related quality of life. interviews with participants, parents and the loop clinic multidisciplinary team will form the basis for a review of the pilot randomised control trial. participants will also fill out 6 validated questionnaires about motivations, the impact of their condition on daily life and their typical exercise levels.

Eligibility criteria:
inclusion criteria: * patients within the liverpool overweight and obesity programme aged 12-18 years * bmi\>30 * receiving input from members of loop clinic at alder hey for weight management * for those prescribed metformin: stable dose for 3-months or more exclusion criteria: * severe learning/behaviour difficulties * severe autism * secondary causes of obesity like cushing's disease * syndromic causes of obesity * patients on glp-1 analogues for obesity * type 2 diabetes mellitus * require an interpreter

Keywords: mobile health technology physical activity exercise exercise prescription/ education exercise adherence
bicuspid valve aortopathy feasibility study

Conditions: Bicuspid Aortic Valve

Summary: in order to determine the effectiveness of medical therapy options to prevent enlargement of the aorta in patients with a bicuspid aortic valve, a randomized study will be planned. this feasibility study will gather accurate data on number needed to screen, changes in medication use over time, and variance of the intended study endpoint.

the study will consider all patients with a bicuspid aortic valve and 1) determine the number of patients needed to be screened for a clinical trial, based on patient eligibility percentages applying specific inclusion and exclusion criteria, 2) for those meeting these criteria, follow changes in and compliance with medical therapy over two years, and 3) in a limited subset of eligible patients, perform mri at baseline and after 2 years to measure the change in aortic area over time.

Eligibility criteria:
inclusion criteria: * bicuspid aortic valve * aortic measurement of 35 - 49 mm on prior imaging study exclusion criteria: * prior aortic valve or thoracic aortic surgery * prior aortic dissection * other condition associated with enlarged aorta including coarctation, marfans, turner syndrome, loeys-dietz, etc. * severe aortic stenosis or regurgitation * contraindication to mri such as claustrophobia or implanted pacer/defibrillator * anticipated pregnancy, surgery, or move outside the area within 2 years
safety and efficacy study of the investigational drug pagoclone, in the treatment of persistent developmental stuttering (pds)

Conditions: Persistent Developmental Stuttering

Summary: this is a research study of the investigational drug, pagoclone, in the treatment of persistent developmental stuttering (pds), which includes frequent repetitions or prolongations of sounds or syllables or words, or frequent hesitations or pauses that disrupt the flow of speech. pagoclone is an investigational drug, so it is not approved by the united states food and drug administration.


Eligibility criteria:
inclusion criteria: * pds defined as dsm-iv-tr criteria * symptoms starting before age 8 * total overall score of 18-36 on the ssi-3 * english speaking, with an 8th grade education * able to understand and cooperate with study requirements with assistance * not pregnant or breastfeeding * able to provide consent exclusion criteria: * no diagnoses of other cns/mental health disorders in the last 6 months * no use of psychotropic medication or other medication for stuttering within 4 weeks prior to screening * no use of non-medicinal stuttering treatments for 5 months prior to the study * no use of illicit drugs or opiates of any kind
application of sers technology in clinical diagnosis and prognosis of lung cancer immunotherapy

Conditions: Lung Cancer

Summary: the aim of this study is to explore the application of surface-enhanced raman scattering (sers) technology and specific pd-l1 detection fluorescent probes in the clinical diagnosis and prognosis of lung cancer immunotherapy, and further promote the rapid diagnosis of lung cancer and the precision of tumor immunotherapy.

the aim of this study is to explore the application of surface-enhanced raman scattering (sers) system in the diagnosis of benign and malignant lung cancer biopsy, and to promote the rapid diagnosis of lung cancer. in addition, the correlation between tumor ph value, pd-l1 expression detected by fluorescent probes and the efficacy and prognosis of immunotherapy was explored. based on this, the immunotherapy efficacy and prognosis prediction models based on patients' clinical information, pd-l1 expression by immunohistochemistry, pd-l1 expression by fluorescent probes and ph value detected by sers were constructed to promote the precision of tumor immunotherapy.

Eligibility criteria:
inclusion criteria: 1. voluntary participation in clinical research; fully understand and informed the study and sign the informed consent form (icf); be willing to follow and be able to complete all trial procedures. 2. male or female aged 18-75 years or more when signing icf. 3. fiberoptic bronchoscopy or percutaneous lung biopsy was performed. 4. lung cancer cannot be surgically resected. 5. at least one measurable target lesion assessed by irrc according to recist 1.1. patients must provide eligible tumor tissue for pd-l1 expression and ph measurement. (7) related laboratory tests suggested that chemotherapy and immunotherapy could be tolerated. exclusion criteria: 1. nsclc patients with unclear diagnosis; 2. patients with contraindications to chemotherapy or immunotherapy. 3. contraindication of lung biopsy. 4. other active malignant tumors within the past year or at the same time. 5. the patient had a known history of psychotropic drug abuse or drug use; she had a history of alcohol abuse. 6. according to the investigator's judgment, the patient had other factors that may lead to early termination of the study.

Keywords: sers probes biopsy immunotherapy prognosis
noninvasive hemodynamics assessment of preterms with successful medical closure of pda

Conditions: Patent Ductus Arteriosus in Preterm Infants

Summary: the aim of our study was to use electrical cardiometry ec to monitor hemodynamic alternations during pharmacological closure of hemodynamically significant patent ductus arteriosus (hspda) in preterm neonates

pda in the first three days of life is a normal physiologic remnant in healthy term neonates. conversely, a pda in preterm neonates causes significant clinical sequelae as a result from left to right shunting. it is widely recognized that a hemodynamically significant pda is known to contribute to increased morbidity and mortality. the increase in pulmonary blood flow in the setting of prematurity leads to pulmonary edema, noncompliant lungs, and worsening of respiratory status. other sequelae of a hemodynamically significant pda include intraventricular hemorrhage, necrotizing enterocolitis, congestive heart failure, and failure to thrive. echocardiography is often used to evaluate hemodynamic significance of pda. in general, pharmacological closure of pda is less successful in infants with ductal diameter \&gt;2mm. lower ductal maximum velocity, which is usually associated with a larger pda or higher pulmonary pressure, is another predictor of treatment failure . the use of echocardiography to gather meaningful hemodynamic data often necessitates serial assessments that can be tedious and labor-intensive. electrical cardiometry (ec) is a non-invasive, impedance-based monitor that provides absolute cardiac output estimates in clinical practice. unlike echocardiography, ec is simple to apply, continuous in measurements and not operator dependent.

Eligibility criteria:
inclusion criteria: * all preterm newborns who were admitted throughout the duration of the research. exclusion criteria: * newborn with congenital heart diseases. * newborn with acquired heart diseases (viral myocarditis) * newborn with dysrhythmias * newborn with symptomatic cardiac dysfunction secondary to extra cardiac diseases * newborn with significant pulmonary hypertension or systemic hypertension

Keywords: pda electrical cardiometry hemodynamics
using a closed-loop system for oxygen delivery (freeo2) to optimize oxygentherapy in patients with copd exacerbation

Conditions: COPD Exacerbation

Summary: aim: the purpose of this study is to evaluate the use feasibility of freeo2 so as to deliver automatically oxygen and to enable a remote medical monitoring with a homogeneous patient population hospitalize for chronic obstructive pulmonary disease (copd)exacerbation. hypothesis: the principal hypothesis is that freeo2 is possible and well-accepted by nurses and medical personnel and there are advantages to use this system. in comparison with the common oxygen delivery (the rotameter), the hypothesis is that freeo2 system will make for a better control of the oxygen saturation in function of designed target, reducing the desaturation time and hyperoxia. we think that oxygen weaning will be faster than classical way if it is automated. in addition, freeo2 could reduce the number of intervention by nurse personnel and to improve the support with centralized monitoring in the freeo2 group.


Eligibility criteria:
inclusion criteria: * patient hospitalized for copd exacerbation * 40 years and older * former or current smoker greater than or equal to 10 pack-years * suspicion or diagnosis of copd at the hospitalisation * acute dyspnea or acute aggravation of dyspnea * respiratory rate greater than or equal to 20 breaths/min * patient needs an oxygen therapy by nasal cannula with oxygen delivered between 0.5 to 8l/min to hold spo2 greater than or equal to 92% exclusion criteria: * imminent indications for intubation * freeo2 system is unavailable at the moment of randomization * patient in isolation (barrier nursing) to the inclusion * patient participates to another clinical trial without possibility of co-enrollment * patient with diagnosis of sleep apnea

Keywords: automatic automation oxygen weaning copd exacerbation